Orlov S. Nicole Schaeffer - Jun 3, 2024 Form 4 Insider Report for INSMED Inc (INSM)

Signature
/s/ S. Nicole Schaeffer, by Michael A. Smith as Attorney-in-fact
Stock symbol
INSM
Transactions as of
Jun 3, 2024
Transactions value $
-$1,883,338
Form type
4
Date filed
6/5/2024, 04:23 PM
Previous filing
May 30, 2024
Next filing
Aug 14, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INSM Common Stock Options Exercise $221K +13.8K +12.64% $16.07 123K Jun 3, 2024 Direct F1
transaction INSM Common Stock Options Exercise $939K +41.3K +33.67% $22.76 164K Jun 3, 2024 Direct F1
transaction INSM Common Stock Sale -$3.04M -55K -33.59% $55.33 109K Jun 3, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INSM Stock Option (right to buy) Options Exercise $0 -13.8K -100% $0.00* 0 Jun 3, 2024 Common Stock 13.8K $16.07 Direct F1, F3
transaction INSM Stock Option (right to buy) Options Exercise $0 -41.3K -100% $0.00* 0 Jun 3, 2024 Common Stock 41.3K $22.76 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2 This is the weighted average sales price representing 55,000 shares sold at prices ranging from $54.69 to $55.65 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
F3 The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable.